Recent submissions

  • Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. 

    Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; Warmuth-Metz, M; Sánchez Aliaga, E; Calmon, R; Hargrave, DR; Cañete, A; Massimino, M; Azizi, AA; Le Deley, M-C; Saran, F; Rousseau, RF; Zahlmann, G; Garcia, J; Vassal, G; Grill, J; Morgan, PS; Jaspan, T (2020-01-10)
    BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ...
  • Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. 

    Menezes, WPD; Silva, VAO; Gomes, INF; Rosa, MN; Spina, MLC; Carloni, AC; Alves, ALV; Melendez, M; Almeida, GC; Silva, LSD; Clara, C; da Cunha, IW; Hajj, GNM; Jones, C; Bidinotto, LT; Reis, RM (2020-02-20)
    The 5'-methylthioadenosine phosphorylase (MTAP) gene is located in the chromosomal region 9p21. MTAP deletion is a frequent event in a wide variety of human cancers; however, its biological role in tumorigenesis remains ...
  • Genetic predisposition for multiple myeloma. 

    Pertesi, M; Went, M; Hansson, M; Hemminki, K; Houlston, RS; Nilsson, B (2020-03)
    Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic ...
  • Topological Tumor Graphs: a graph-based spatial model to infer stromal recruitment for immunosuppression in melanoma histology. 

    Failmezger, H; Muralidhar, S; Rullan, A; de Andrea, CE; Sahai, E; Yuan, Y (2019-12-24)
    Despite the advent of immunotherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome. The successful application of immunotherapy requires in-depth understanding of the biological basis ...
  • Computational image analysis of T-cell infiltrates in resectable gastric cancer: association with survival and molecular subtypes 

    Challoner, B; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; Semiannikova, M; Newey, A; Barber, L; Mansfield, D; Hewitt, L; Saito, Y; Davarzani, N; Starling, N; Melcher, A; Grabsch, H; Gerlinger, M
    Background: Gastric and gastro-oesophageal junction cancers (GCs) frequently recur after resection but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ...
  • Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. 

    Shah, V; Sherborne, AL; Johnson, DC; Ellis, S; Price, A; Chowdhury, F; Kendall, J; Jenner, MW; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; Davies, FE; Cook, G; Cairns, DA; Houlston, RS; Jackson, G; Kaiser, MF; on behalf of NCRI Haematology Clinical Studies Group (2020-03-11)
  • Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. 

    Cresswell, GD; Nichol, D; Spiteri, I; Tari, H; Zapata, L; Heide, T; Maley, CC; Magnani, L; Schiavon, G; Ashworth, A; Barry, P; Sottoriva, A (2020-03-27)
    Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies. However, exploiting ctDNA to determine how a patient's cancer is evolving ...
  • Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes 

    Jones, C; Mackay, A; Izquierdo, E; Temelso, S; Carvalho, D; Molinari, V; Burford, A; Howell, L; Natrajan, R; Boult, J; Robinson, S
  • Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. 

    Lau, D; Kalaitzaki, E; Church, DN; Pandha, H; Tomlinson, I; Annels, N; Gerlinger, M; Sclafani, F; Smith, G; Begum, R; Crux, R; Gillbanks, A; Wordsworth, S; Chau, I; Starling, N; Cunningham, D; Dhillon, T (2020-02)
    BACKGROUND:10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational ...
  • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

    James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
    IMPORTANCE:The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...
  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

    James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
    BACKGROUND:Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
  • Investigating the mehcanisms of drug resistance in gastro-intestinal cancers 

    Spain, G (2020-03-31)
    Despite many effective therapies for gastro-intestinal (GI) cancers, both primary and acquired mechanisms of resistance commonly occur. The subclonal complexity of intra-tumoural heterogeneity in these cancers further ...
  • IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche. 

    Wamaitha, SE; Grybel, KJ; Alanis-Lobato, G; Gerri, C; Ogushi, S; McCarthy, A; Mahadevaiah, SK; Healy, L; Lea, RA; Molina-Arcas, M; Devito, LG; Elder, K; Snell, P; Christie, L; Downward, J; Turner, JMA; Niakan, KK (2020-02-07)
    Our understanding of the signalling pathways regulating early human development is limited, despite their fundamental biological importance. Here, we mine transcriptomics datasets to investigate signalling in the human ...
  • Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. 

    Schmidt, AF; Holmes, MV; Preiss, D; Swerdlow, DI; Denaxas, S; Fatemifar, G; Faraway, R; Finan, C; Valentine, D; Fairhurst-Hunter, Z; Hartwig, FP; Horta, BL; Hypponen, E; Power, C; Moldovan, M; van Iperen, E; Hovingh, K; Demuth, I; Norman, K; Steinhagen-Thiessen, E; Demuth, J; Bertram, L; Lill, CM; Coassin, S; Willeit, J; Kiechl, S; Willeit, K; Mason, D; Wright, J; Morris, R; Wanamethee, G; Whincup, P; Ben-Shlomo, Y; McLachlan, S; Price, JF; Kivimaki, M; Welch, C; Sanchez-Galvez, A; Marques-Vidal, P; Nicolaides, A; Panayiotou, AG; Onland-Moret, NC; van der Schouw, YT; Matullo, G; Fiorito, G; Guarrera, S; Sacerdote, C; Wareham, NJ; Langenberg, C; Scott, RA; Luan, J; Bobak, M; Malyutina, S; Pająk, A; Kubinova, R; Tamosiunas, A; Pikhart, H; Grarup, N; Pedersen, O; Hansen, T; Linneberg, A; Jess, T; Cooper, J; Humphries, SE; Brilliant, M; Kitchner, T; Hakonarson, H; Carrell, DS; McCarty, CA; Lester, KH; Larson, EB; Crosslin, DR; de Andrade, M; Roden, DM; Denny, JC; Carty, C; Hancock, S; Attia, J; Holliday, E; Scott, R; Schofield, P; O'Donnell, M; Yusuf, S; Chong, M; Pare, G; van der Harst, P; Said, MA; Eppinga, RN; Verweij, N; Snieder, H; Lifelines Cohort authors; Christen, T; Mook-Kanamori, DO; ICBP Consortium; Gustafsson, S; Lind, L; Ingelsson, E; Pazoki, R; Franco, O; Hofman, A; Uitterlinden, A; Dehghan, A; Teumer, A; Baumeister, S; Dörr, M; Lerch, MM; Völker, U; Völzke, H; Ward, J; Pell, JP; Meade, T; Christophersen, IE; Maitland-van der Zee, AH; Baranova, EV; Young, R; Ford, I; Campbell, A; Padmanabhan, S; Bots, ML; Grobbee, DE; Froguel, P; Thuillier, D; Roussel, R; Bonnefond, A; Cariou, B; Smart, M; Bao, Y; Kumari, M; Mahajan, A; Hopewell, JC; Seshadri, S; METASTROKE Consortium of the ISGC; Dale, C; Costa, RPE; Ridker, PM; Chasman, DI; Reiner, AP; Ritchie, MD; Lange, LA; Cornish, AJ; Dobbins, SE; Hemminki, K; Kinnersley, B; Sanson, M; Labreche, K; Simon, M; Bondy, M; Law, P; Speedy, H; Allan, J; Li, N; Went, M; Weinhold, N; Morgan, G; Sonneveld, P; Nilsson, B; Goldschmidt, H; Sud, A; Engert, A; Hansson, M; Hemingway, H; Asselbergs, FW; Patel, RS; Keating, BJ; Sattar, N; Houlston, R; Casas, JP; Hingorani, AD (2019-10-29)
    BACKGROUND:We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. METHODS:Published and individual participant ...
  • Measuring single cell divisions in human tissues from multi-region sequencing data. 

    Werner, B; Case, J; Williams, MJ; Chkhaidze, K; Temko, D; Fernández-Mateos, J; Cresswell, GD; Nichol, D; Cross, W; Spiteri, I; Huang, W; Tomlinson, IPM; Barnes, CP; Graham, TA; Sottoriva, A (2020-02-25)
    Both normal tissue development and cancer growth are driven by a branching process of cell division and mutation accumulation that leads to intra-tissue genetic heterogeneity. However, quantifying somatic evolution in ...
  • Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. 

    Loupakis, F; Depetris, I; Biason, P; Intini, R; Prete, AA; Leone, F; Lombardi, P; Filippi, R; Spallanzani, A; Cascinu, S; Bonetti, LR; Maddalena, G; Valeri, N; Sottoriva, A; Zapata, L; Salmaso, R; Munari, G; Rugge, M; Dei Tos, AP; Golovato, J; Sanborn, JZ; Nguyen, A; Schirripa, M; Zagonel, V; Lonardi, S; Fassan, M (2020-01-22)
    BACKGROUND:Immunotherapy with immune checkpoint inhibitors (ICIs) is highly effective in microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); however, specific predictive biomarkers are lacking. ...
  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. 

    Berthon, C; Raffoux, E; Thomas, X; Vey, N; Gomez-Roca, C; Yee, K; Taussig, DC; Rezai, K; Roumier, C; Herait, P; Kahatt, C; Quesnel, B; Michallet, M; Recher, C; Lokiec, F; Preudhomme, C; Dombret, H (2016-04)
    Bromodomain and extraterminal (BET) proteins are chromatin readers that preferentially affect the transcription of genes with super-enhancers, including oncogenes. BET proteins bind acetylated histone tails via their ...
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. 

    Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; Fitzgibbons, PL; Hayes, DF; Lakhani, SR; Chavez-MacGregor, M; Perlmutter, J; Perou, CM; Regan, MM; Rimm, DL; Symmans, WF; Torlakovic, EE; Varella, L; Viale, G; Weisberg, TF; McShane, LM; Wolff, AC (2020-01-13)
    PURPOSE:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS:A multidisciplinary ...
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. 

    Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; Fitzgibbons, PL; Hayes, DF; Lakhani, SR; Chavez-MacGregor, M; Perlmutter, J; Perou, CM; Regan, MM; Rimm, DL; Symmans, WF; Torlakovic, EE; Varella, L; Viale, G; Weisberg, TF; McShane, LM; Wolff, AC (2020-01-13)
    PURPOSE.—:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—:A ...
  • Measuring Clonal Evolution in Cancer with Genomics. 

    Williams, MJ; Sottoriva, A; Graham, TA (2019-08)
    Cancers originate from somatic cells in the human body that have accumulated genetic alterations. These mutations modify the phenotype of the cells, allowing them to escape the homeostatic regulation that maintains normal ...

View more